EGFR and neoplasm: The A431 tumor cell line exhibited lower IC50 values than the HCB-541 cell line only for the EGFR family of afatinib (0.49 ± 0.3 μM), allitinib (0.37 ± 0.9 μM), erlotinib (13.49 ± 0.3 μM), and cetuximab (101.0 ± 0.7 μg/mL), due to its overexpression of this receptor tyrosine kinase.